SUPN News and Press, Supernus Pharmaceuticals Inc. From 11/02/20

Supernus Pharmaceuticals (NASDAQ:SUPN) is scheduled to announce Q3 earnings results on Tuesday, November 3rd, after market close.The consensus EPS Estimate is $0.27 (-50.0% Y/Y) and the consensus Revenue Estimate is $130.76M (+28.0% Y/Y).Over the last 2 years, SUPN has beaten EPS estimates 75...

ROCKVILLE, Md., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report busines...

A dashboard with metrics in healthcare industries. Value and quality scores, and their evolution since last month. A list of cheap stocks. For further details see: Healthcare: XLV Survey For October

Supernus Pharmaceuticals (SUPN) appoints James Kelly as Chief Financial Officer, effective October 12. He brings over 25 years of experience, and most recently he served as Chief Financial Officer and Treasurer of Vanda Pharmaceuticals.Greg Patrick, who will be retiring from hi...

ROCKVILLE, Md., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced the appointment of James Kelly as Chief Fi...

Despite a volatile quarter, our diversified portfolio delivered some nice returns in several sectors. Technology, GSMs (gold, silver, miners) and blockchain enterprises clearly outperformed other segments. We remain quite bullish on GSMs and digital assets, in particular, going fo...

Supernus is preparing for an imminent launch of SPN-812 with a PDUFA target action date of 11/08/20. The company is prepared for the tough competition SPN-812 will face as it competes in a crowded field for ADHD therapies. Supernus recently submitted its NDA for its Apomorphine In...

Supernus is solidly on track for a new record of net sales this year and is still generating huge amounts of free cash flow. Despite this, Supernus' stock has dropped off substantially of late. I still view Supernus as a strong value play at present. For further details see:...

This article series shows every month a dashboard with aggregate industry metrics in healthcare. Most of the companies used to calculate these metrics are holdings of the Health Care Select Sector SPDR ETF ( XLV ). Therefore, this is also a top-down survey of XLV. Shortcut If you are use...

ROCKVILLE, Md., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that it has submitted a New Drug Applicat...